On November 13, Veradermics, Inc. fell 4.37% in Regular Trading to $129.26 per share, with turnover of $12.28 million.
The move came as the market continued to digest the company’s recently reported third-quarter results, clinical progress for VDPHL01 and updated analyst views, even after several firms raised price targets.
Veradermics, Inc. reported a third-quarter net loss of $21.0 million, wider than the $20.1 million loss a year earlier but better than the $26.5 million loss expected by analysts, with no revenue reported. Cash, cash equivalents and marketable securities stood at $798.4 million at September 30, which management said should fund operations into 2030. On the clinical side, VDPHL01 met co-primary efficacy endpoints in two registration-directed male pattern hair loss studies, while initial topline data from the female registration-directed trial are expected in the first half of 2027. Separately, Leerink maintained a Buy rating and raised its price target to $185.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments